A phase 2, multicenter study to evaluate the efficacy and safety using autologous tumor infiltrating lymphocytes (LN-145) in patients with recurrent, metastatic, or persistent cervical carcinoma.

Amir A. Jazaeri,Robert P. Edwards,Robert M. Wenham,Koji Matsuo,Gini F. Fleming,David M. O'Malley,Brian M. Slomovitz,Bradley J. Monk,Robert James Brown,Samuel Suzuki,Igor Gorbatchevsky,Maria Fardis,Emese Zsiros

A phase 2, multicenter study to evaluate the efficacy and safety using autologous tumor infiltrating lymphocytes (LN-145) in patients with recurrent, metastatic, or persistent cervical carcinoma.

2018

Amir A. Jazaeri
Robert P. Edwards
Robert M. Wenham
Koji Matsuo
Gini F. Fleming
David M. O'Malley
Brian M. Slomovitz
Bradley J. Monk
Robert James Brown
Samuel Suzuki
Igor Gorbatchevsky
Maria Fardis
Emese Zsiros

TPS5604Background: Adoptive cell therapy (ACT) with tumor-infiltrating lymphocytes (TIL) has demonstrated efficacy in the treatment of immunogenic tumors with high mutation loads, such as melanoma,...

Keywords:

Carcinoma
Cancer research
Pathology
Medicine
Tumor-infiltrating lymphocytes
cervical carcinoma
autologous tumor
Melanoma
Oncology
in patient
Internal medicine
multicenter study
Cell therapy

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations